Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$2.57
-4.8%
$2.25
$1.60
$16.55
$190.77M1.111.03 million shs587,171 shs
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
$19.13
$17.67
$14.58
$27.28
$181.95M1.166,000 shs53,207 shs
Modular Medical, Inc. stock logo
MODD
Modular Medical
$0.85
-3.4%
$0.95
$0.68
$2.65
$46.11M0.33207,519 shs7,138 shs
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
$5.43
-0.9%
$5.42
$3.50
$7.55
$205.47M0.542,144 shs50,544 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
0.00%+7.53%+0.39%+4.47%-81.38%
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
0.00%+4.88%+13.60%-17.29%+3.80%
Modular Medical, Inc. stock logo
MODD
Modular Medical
0.00%-0.33%-18.27%+10.68%-47.85%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
0.00%-2.34%+6.26%-3.89%-24.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.506 of 5 stars
4.60.00.00.02.72.50.6
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
4.7522 of 5 stars
3.53.00.84.92.03.31.9
Modular Medical, Inc. stock logo
MODD
Modular Medical
1.5918 of 5 stars
0.05.00.00.02.53.30.0
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
2.9031 of 5 stars
3.63.00.00.02.52.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.18
Buy$12.50386.38% Upside
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
3.00
Buy$27.0041.14% Upside
Modular Medical, Inc. stock logo
MODD
Modular Medical
0.00
N/AN/AN/A
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
3.25
Buy$10.7597.97% Upside

Current Analyst Ratings Breakdown

Latest MODD, CATX, TLSI, and LAKE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
5/13/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
4/15/2025
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $23.00
4/7/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $10.00
3/31/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/28/2025
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
3/27/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $15.00
3/26/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.00
3/26/2025
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
3/25/2025
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/19/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$1.43M133.40N/AN/A$2.67 per share0.96
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
$167.21M1.09$1.06 per share18.07$16.76 per share1.14
Modular Medical, Inc. stock logo
MODD
Modular Medical
N/AN/AN/AN/A$0.25 per shareN/A
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
$32.14M6.39N/AN/A($0.98) per share-5.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
$5.43M-$2.38N/A11.52N/A-0.42%1.66%1.14%6/9/2025 (Estimated)
Modular Medical, Inc. stock logo
MODD
Modular Medical
-$17.47M-$0.53N/AN/AN/A-197.97%-162.31%6/20/2025 (Estimated)
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$59.04M-$1.12N/AN/AN/A-206.24%N/A-236.83%8/13/2025 (Estimated)

Latest MODD, CATX, TLSI, and LAKE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/9/2025Q1 2026
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
$0.27N/AN/AN/A$48.84 millionN/A
5/15/2025Q1 2025
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$0.20-$0.33-$0.13-$0.39$9.04 million$9.17 million
4/9/2025Q4 2025
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
$0.43-$0.54-$0.97-$2.42$47.10 million$46.60 million
3/27/2025Q4 2024
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$0.35-$0.35N/A-$0.40$8.12 million$8.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
$0.120.63%N/AN/A 1 Years
Modular Medical, Inc. stock logo
MODD
Modular Medical
N/AN/AN/AN/AN/A
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
N/AN/AN/AN/AN/A

Latest MODD, CATX, TLSI, and LAKE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/1/2025
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
quarterly$0.030.71%5/15/20255/15/20255/22/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/A
9.60
9.60
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
0.25
4.23
1.77
Modular Medical, Inc. stock logo
MODD
Modular Medical
N/A
5.30
5.30
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
N/A
2.40
2.00

Institutional Ownership

CompanyInstitutional Ownership
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
71.69%
Modular Medical, Inc. stock logo
MODD
Modular Medical
27.47%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
2.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
7074.23 million65.21 millionOptionable
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
1,8009.51 million9.10 millionOptionable
Modular Medical, Inc. stock logo
MODD
Modular Medical
2054.25 million32.35 millionNot Optionable
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
10637.84 million20.49 millionNot Optionable

Recent News About These Companies

Roth Capital Issues Pessimistic Estimate for TLSI Earnings
Cantor Fitzgerald Has Negative View of TLSI FY2025 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Perspective Therapeutics stock logo

Perspective Therapeutics NYSE:CATX

$2.57 -0.13 (-4.81%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$2.57 0.00 (0.00%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Lakeland Industries stock logo

Lakeland Industries NASDAQ:LAKE

$19.13 0.00 (0.00%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$19.06 -0.07 (-0.37%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lakeland Industries, Inc. manufactures and sells industrial protective clothing and accessories for the industrial and public protective clothing market worldwide. It offers firefighting and heat protective apparel to protect against fire; high-end chemical protective suits to provide protection from highly concentrated, toxic and/or lethal chemicals, and biological toxins; and limited use/disposable protective clothing, such as coveralls, laboratory coats, shirts, pants, hoods, aprons, sleeves, arm guards, caps, and smocks. The company provides durable woven garments, including electrostatic dissipative apparel used in electronics clean rooms; flame resistant meta aramid, para aramid, and FR cotton coveralls/pants/jackets used in petrochemical, refining operations, and electrical utilities; FR fabrics; and cotton and polycotton coveralls, lab coats, pants, and shirts. In addition, it provides high visibility clothing comprising reflective apparel, including vests, T-shirts, sweatshirts, jackets, coats, raingear, jumpsuits, hats, and gloves; and gloves and sleeves that are used in the automotive, glass, and metal fabrication industries. The company sells its products to a network of safety and industrial supply distributors through in-house sales teams, customer service group, and independent sales representatives. It serves end users, such as integrated oil, chemical/petrochemical, automobile, steel, glass, construction, smelting, cleanroom, janitorial, pharmaceutical, and high technology electronics manufacturers, as well as scientific, medical laboratories, and the utilities industry; and federal, state, and local governmental agencies and departments. Lakeland Industries, Inc. was incorporated in 1982 and is headquartered in Huntsville, Alabama.

Modular Medical stock logo

Modular Medical NASDAQ:MODD

$0.85 -0.03 (-3.41%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$0.86 +0.01 (+1.18%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.

TriSalus Life Sciences stock logo

TriSalus Life Sciences NASDAQ:TLSI

$5.43 -0.05 (-0.91%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$5.00 -0.43 (-7.92%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.